
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-04-05-2017
- Volume 12
- Issue 4
Permira Funds to Acquire LSNE
Permira will acquire LSNE, a CDMO for the pharmaceutical and medical device markets.
Permira, the global private equity firm, announced on March 27, 2017 that a company backed by the Permira funds has signed a definitive agreement to acquire Lyophilization Services of New England, Inc (LSNE), a contract development and manufacturing organization for the pharmaceutical and medical device markets, in partnership with management. As part of the transaction, LSNE Founder and Chief Executive Officer Matt Halvorsen will maintain a significant equity stake in the company and will continue to lead the company in his current role.
In conjunction with the transaction, Claes Glassell, the former CEO of CMC Biologics and a 30-year pharmaceutical industry veteran, will join as chairman of the board of LSNE in support of the management team and growth strategy. The Permira funds’ investment will support the company’s growth, including expanding the company’s capacity and address commercial-stage opportunities, extending its capabilities in manufacturing and development services, and pursuing selective acquisitions.
Source:
Articles in this issue
over 8 years ago
Seeking Solutions for Oral Delivery of Biologic APIsover 8 years ago
Should More Pharma Products be Made in the USA?over 8 years ago
Technology to the Rescue for Data Integrity Challenges?over 8 years ago
Putting GS1’s EPCIS Standards to the Testover 8 years ago
RSSL Expands Particle Characterization Capabilitiesover 8 years ago
Butterworth Laboratories Expands UK Lab Operationsover 8 years ago
Eurofins Scientific Invests in New UK Facilityover 8 years ago
Hitachi Chemical Purchases PCT From Caladrius Biosciencesover 8 years ago
JRS Pharma Adds Povidone Product LineNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





